The Permanent Representatives Committee is asked to approve a representative of Kerry Group (transparency register number: 082799927198-85) attending the Working Party on Competitiveness and Growth (High Level) on 7 September 2026, according to a Council document published on 9 July 2026. The working party will exchange views on 'Unlocking Europe's biotechnology potential', and the external speaker would share experience with biotechnology solutions and transformation from a taste and nutrition partner perspective for food, beverage and pharmaceutical industries. The Chair considers the invitation in the interest of the Council and in line with the framework for occasional presence of third parties at Council or preparatory body meetings. The Permanent Representatives Committee must approve the attendance.
The document, an 'I' item note dated 15 July 2026, sets the stage for a procedural decision by Coreper. If approved, Kerry Group would be the first external stakeholder to address the high-level working party on this topic. The meeting reflects the Council's ongoing focus on biotechnology as a strategic sector for EU competitiveness. No prior coverage of this specific invitation exists in recent records.
Stakeholder impact - EU regulatory bodies: The Council's preparatory bodies gain direct industry input on biotechnology, potentially informing future policy. However, the ad-hoc nature of the invitation may raise questions about balanced stakeholder representation. - Kerry Group: The company would have a platform to influence EU policy discussions on biotechnology, potentially shaping regulations that affect its business in food, beverage, and pharma sectors. The invitation signals recognition of its expertise. - EU biotechnology sector: The working party's focus on unlocking biotechnology potential could lead to more supportive EU policies, benefiting the sector. However, the involvement of a single large player may overshadow smaller innovators. - EU consumers: If the exchange leads to policies that accelerate biotechnology adoption, consumers could see faster innovation in food and pharma products. Conversely, concerns about corporate influence on regulation may arise.
Institutional follow-up The Permanent Representatives Committee is expected to decide on the attendance request in its upcoming meeting. If approved, the working party on 7 September 2026 will proceed with the external speaker. The outcome of the working party's exchange may feed into broader Council discussions on biotechnology, including potential legislative initiatives.